Recent findings from the RECOVER initiative highlight a connection between persistent viral presence and long COVID symptoms, although isolating live virus remains a significant technical challenge.

Evidence suggests that prolonged shedding of viral RNA is linked to an increased risk of developing long COVID, particularly among individuals who experience mild COVID-19.

A perspective article in the Medical Journal of Australia emphasizes that the persistent presence of the virus or its remnants may play a crucial role in the development of long COVID.

Research has shown replicating viral RNA in blood and various tissues, including the gastrointestinal tract, up to four months after infection, indicating potential hidden reservoirs.

Identifying live virus is essential, as it can be targeted by antiviral treatments, unlike inactive viral fragments, underscoring the need for further investigation.

Raising awareness about the concept of 'long infection' can help demystify long COVID and stress the importance of preventive measures against reinfection.

There is a call for researchers and policymakers to expedite clinical trials of existing antivirals and explore unconventional therapies, such as metformin, to alleviate long COVID symptoms.

Approximately 5-10% of individuals who contract COVID-19 experience long COVID, characterized by lingering symptoms that persist for three months or longer.

Long COVID can impact individuals of all ages, with the most significant effects observed in those aged 30 to 49 years.

To mitigate the risk of long COVID, individuals are advised to maintain clean indoor air, use high-quality masks, test and isolate when positive, and stay updated on vaccinations.

In immunocompromised individuals, persistent infections could lead to the emergence of new variants, continuing to cause symptoms long after acute COVID-19 has resolved.

Investment in novel drug development and rapid clinical trial platforms is crucial for translating scientific advancements into effective treatments for long COVID.